204 related articles for article (PubMed ID: 18040144)
1. Radioimmunotherapy for non-hodgkin lymphoma : historical perspective and current status.
Emmanouilides C
J Clin Exp Hematop; 2007 Nov; 47(2):43-60. PubMed ID: 18040144
[TBL] [Abstract][Full Text] [Related]
2. [Radioimmunotherapy for non-Hodgkin lymphoma: historical development and current status].
Emmanouilides C
Rev Esp Med Nucl; 2006; 25(1):42-54. PubMed ID: 16540013
[TBL] [Abstract][Full Text] [Related]
3. Radioimmunotherapy for non-Hodgkin's lymphoma.
Emmanouilides C
Semin Oncol; 2003 Aug; 30(4):531-44. PubMed ID: 12939722
[TBL] [Abstract][Full Text] [Related]
4. Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma.
Hagenbeek A; Lewington V
Ann Oncol; 2005 May; 16(5):786-92. PubMed ID: 15802280
[TBL] [Abstract][Full Text] [Related]
5. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
Marcus R
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
[TBL] [Abstract][Full Text] [Related]
6. Rituxan immunotherapy and zevalin radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
White CA
Curr Pharm Biotechnol; 2003 Aug; 4(4):221-38. PubMed ID: 14529425
[TBL] [Abstract][Full Text] [Related]
7. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
8. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.
Wagner HN; Wiseman GA; Marcus CS; Nabi HA; Nagle CE; Fink-Bennett DM; Lamonica DM; Conti PS
J Nucl Med; 2002 Feb; 43(2):267-72. PubMed ID: 11850494
[TBL] [Abstract][Full Text] [Related]
9. Future directions in radioimmunotherapy for B-cell lymphoma.
Horning SJ
Semin Oncol; 2003 Dec; 30(6 Suppl 17):29-34. PubMed ID: 14710401
[TBL] [Abstract][Full Text] [Related]
10. Novel concepts in radioimmunotherapy for non-Hodgkin's lymphoma.
Schaefer-Cutillo J; Friedberg JW; Fisher RI
Oncology (Williston Park); 2007 Feb; 21(2):203-12; discussion 214, 217, 221. PubMed ID: 17396483
[TBL] [Abstract][Full Text] [Related]
11. Nursing a patient during and after 90Y-ibritumomab tiuxetan (Zevalin) therapy.
Clayton J
Leuk Lymphoma; 2003; 44 Suppl 4():S49-55. PubMed ID: 15154742
[TBL] [Abstract][Full Text] [Related]
12. A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma.
Durando M; Gopal AK; Tuscano J; Persky D
Oncologist; 2024 Apr; 29(4):278-288. PubMed ID: 38207010
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy and Autologous Stem-Cell Transplantation in the Treatment of B-Cell Non-Hodgkin Lymphoma.
Shimoni A; Zwas ST
Semin Nucl Med; 2016 Mar; 46(2):119-25. PubMed ID: 26897716
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma.
Witzig TE
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S91-5. PubMed ID: 11587375
[TBL] [Abstract][Full Text] [Related]
15. Radioimmunotherapy for B-cell non-hodgkin lymphomas.
Tomblyn M
Cancer Control; 2012 Jul; 19(3):196-203. PubMed ID: 22710895
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunotherapy of relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Dillman RO
Curr Hematol Rep; 2003 Jan; 2(1):30-7. PubMed ID: 12901152
[TBL] [Abstract][Full Text] [Related]
17. Radioimmunotherapy for indolent B-cell non-Hodgkin lymphoma in relapsed, refractory and transformed disease.
Visser OJ; Perk LR; Zijlstra JM; van Dongen GA; Huijgens PC; van de Loosdrecht AA
BioDrugs; 2006; 20(4):201-7. PubMed ID: 16831019
[TBL] [Abstract][Full Text] [Related]
18. The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma.
Cheson BD
BioDrugs; 2005; 19(5):309-22. PubMed ID: 16207072
[TBL] [Abstract][Full Text] [Related]
19. Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma.
Witzig TE
Drugs Today (Barc); 2004 Feb; 40(2):111-9. PubMed ID: 15045033
[TBL] [Abstract][Full Text] [Related]
20. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
